Key Highlights
- Anthropic keeps Claude Fable 5 in subscriptions: After postponing the cutoff three times over five weeks, Anthropic will keep Fable available in Max and Team Premium tiers (with reduced caps), while lower tiers get a one-time $100 credit before moving to pay-per-use — a rare public climbdown driven by demand it admits it couldn’t predict.
- NVIDIA’s drug-discovery AI factory scales up: Bristol Myers Squibb deployed a second DGX SuperPOD on eight DGX Vera Rubin NVL72 systems, claiming up to 10x performance per megawatt and putting agentic drug-discovery workflows in the hands of “literally every scientist.”
New Products & Tools
Anthropic’s Fable survives the subscription axe — Rundown
Anthropic ended weeks of uncertainty by confirming Claude Fable 5 will stay in its Max and Team Premium subscription tiers, though with lower usage caps; lower-tier users get a one-time $100 credit before transitioning to pay-per-use pricing. The reversal — after three postponed deadlines — comes amid competitive pressure from OpenAI’s GPT-5.6 Sol expanding its limits and Moonshot’s near-frontier Kimi K3, with Anthropic pledging added compute capacity to improve access.
Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin — NVIDIA
BMS deployed its second NVIDIA DGX SuperPOD — eight DGX Vera Rubin NVL72 systems billed as the most powerful, energy-efficient AI cluster in life sciences — unifying old and new infrastructure into a single global data plane accessible via natural-language commands and the BioNeMo Agent Toolkit. The company reports its existing SuperPOD already cut target-identification work by weeks and drove a “Predict First” lead-optimization method that prioritizes which molecules to synthesize.
References
- Anthropic’s Fable survives the subscription axe — Rundown, 2026-07-20 [blog]
- Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin — NVIDIA, 2026-07-20 [blog]